Tidemark’s Ionis Pharmaceuticals IONS Stock Holding History

Tidemark’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-200	Closed	-$6.99K	–	706
2024 Q4	$6.99K	Buy	+200	New	+$7.48K	﹤0.01%	475

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Tidemark's IONS Position: Q1 2025 in Review

Tidemark sold out of Ionis Pharmaceuticals (IONS) in Q1 2025, closing a stake of 200 shares — an estimated $6.99K sold.

Tidemark first reported a position in IONS in Q4 2024 and held it in 1 quarter. The position peaked at $6.99K in Q4 2024. 343 funds tracked by Wall St. Rank hold IONS as of Q1 2025.

Tidemark reported no remaining Ionis Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
Tidemark sold 200 Ionis Pharmaceuticals shares in Q1 2025, an estimated $6.99K.
Tidemark first reported a position in Ionis Pharmaceuticals in Q4 2024 and held it in 1 quarter.
Tidemark's Ionis Pharmaceuticals position peaked at $6.99K in Q4 2024.
343 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2025.

Based on Tidemark's 13F filing for Q1 2025, filed 9 May 2025.